Liver Disease in Pregnancy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-09

Study Completion Date

2025-04-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Liver Diseases in pregnancy represents rare disorders and current data is derived primarily from single centres and retrospective cohorts. Moreover, the population prevalence of these diseases is low and to-date, it has proven difficult to generate reliable data at a patient level.

This is a multi-center, prospective cohort study that will open at 3 centers within the UK; and 4 centers in the European Union. The investigators will aim to collect data and blood samples at various time points, for patients presenting with liver disease during pregnancy. The main rationale behind this study is to establish a platform that enables detailed review of the outcomes of these rare diseases; to help classify and stratify patients according to risk and develop interventional studies and care pathways to improve overall outcome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Serum Autotaxin Levels in Cholestasis of Pregnancy

NCT02480478

Intrahepatic Cholestasis of Pregnancy

UNKNOWN

Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study

NCT03056612

Liver Cirrhosis With Acute Decompensation

COMPLETED

Study of the Drivers of Late Diagnosis of Alcohol Related Diseases, Alone or in Combination With Metabolic Dysfunconal Associated Fatty Liver Disease, Implementation and Evaluation of Itnerventions to Reduce Its Burden.

NCT06403332

RECRUITING NA

Unknown Cause of Acute Liver Failure

NCT02041637

Liver Failure Unknown Etiology

COMPLETED

Characterization of Metabolomic Fingerprints in Patients With Acute Liver Failure and Acute-on-chronic Liver Failure With Hepatic Encephalopathy

NCT05772585

Hepatic Encephalopathy Acute Liver Failure Acute on Chronic Liver Failure

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objectives of the study are as follows:

Primary Objective:

To determine the characteristic physiological and biological changes exhibited by females who develop the following liver diseases during pregnancy.

* Acute fatty liver of pregnancy
* Severe cholestasis of pregnancy
* Severe HELLP syndrome/hypertensive disease
* Pre-existing cirrhosis and pregnancy This will be determined through analysis of the standard of care imaging (Liver Ultrasound and Transient Elastography) and blood results (liver function tests, white blood cells, platelets and scoring systems for assessing the severity of liver disease (ALBI, APRI, FIB4 and ELF scores). These results will be analysed over the course of the participant's pregnancy and again at delivery, to explore any particularly distinguishing parameter changes for each disease group.

Secondary Objectives

1. To determine the change in the reported quality of life of these participants either from diagnosis of pregnancy-associated liver disease or confirmation of pregnancy for pre-existing cirrhotic patients - up to 3 months' post-delivery.
2. To determine the mitochondrial DNA content of blood from patients with Acute Fatty Liver of Pregnancy.
3. Create an associated pan-European bio-resource (whole blood and serum) collection, which will offer an opportunity for ongoing collaborative translational research. Each participant will be given the option of donating additional research samples (15ml) of blood at each visit under the study for the bio-resource.

Data from cirrhotic patients will be collected from pre-pregnancy and during the first, second and third trimesters as well as at delivery and post-partum. Data from patients with AFLP/HELLP/ICP will be collected from pre-diagnosis, at first presentation of liver disease, at peak of liver disease, during the recovery period from peak liver disease as well as at delivery and post-partum.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy Disease Cirrhosis, Liver HELLP Syndrome AFLP - Acute Fatty Liver of Pregnancy Intrahepatic Cholestasis of Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cirrhosis in pregnancy

Cirrhotic patients with a confirmed pregnancy will be placed into Cohort 1.

No interventions assigned to this group

Pregnancy-associated liver diseases

Patients who develop Acute Fatty Liver of Pregnancy, HELLP Syndrome / Intrahepatic Cholestasis of pregnancy will be placed into Cohort 2.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Female patients older than 18 years of age, willing and able to sign written informed consent.
2. Pregnant and presenting with any one of the following conditions (confirmed by local diagnosis):

* Acute fatty liver of pregnancy
* Severe cholestasis of pregnancy
* Severe HELLP syndrome /hypertensive disease
* Pre-existing cirrhosis and pregnancy
3. Able to provide written informed consent
4. Willing to provide access to records to necessary data can be collected.
5. Willing to complete additional quality of life questionnaires as per protocol.
6. Willing to consider donation of optional blood samples as per protocol.